Cargando…
The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780529/ https://www.ncbi.nlm.nih.gov/pubmed/36568122 http://dx.doi.org/10.3389/fendo.2022.1097968 |
| _version_ | 1784856860302508032 |
|---|---|
| author | Forzano, Imma Mone, Pasquale Varzideh, Fahimeh Jankauskas, Stanislovas S. Kansakar, Urna De Luca, Antonio Santulli, Gaetano |
| author_facet | Forzano, Imma Mone, Pasquale Varzideh, Fahimeh Jankauskas, Stanislovas S. Kansakar, Urna De Luca, Antonio Santulli, Gaetano |
| author_sort | Forzano, Imma |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9780529 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-97805292022-12-24 The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension Forzano, Imma Mone, Pasquale Varzideh, Fahimeh Jankauskas, Stanislovas S. Kansakar, Urna De Luca, Antonio Santulli, Gaetano Front Endocrinol (Lausanne) Endocrinology Frontiers Media S.A. 2022-12-09 /pmc/articles/PMC9780529/ /pubmed/36568122 http://dx.doi.org/10.3389/fendo.2022.1097968 Text en Copyright © 2022 Forzano, Mone, Varzideh, Jankauskas, Kansakar, De Luca and Santulli https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Endocrinology Forzano, Imma Mone, Pasquale Varzideh, Fahimeh Jankauskas, Stanislovas S. Kansakar, Urna De Luca, Antonio Santulli, Gaetano The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension |
| title | The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension |
| title_full | The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension |
| title_fullStr | The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension |
| title_full_unstemmed | The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension |
| title_short | The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension |
| title_sort | selective aldosterone synthase inhibitor baxdrostat significantly lowers blood pressure in patients with resistant hypertension |
| topic | Endocrinology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780529/ https://www.ncbi.nlm.nih.gov/pubmed/36568122 http://dx.doi.org/10.3389/fendo.2022.1097968 |
| work_keys_str_mv | AT forzanoimma theselectivealdosteronesynthaseinhibitorbaxdrostatsignificantlylowersbloodpressureinpatientswithresistanthypertension AT monepasquale theselectivealdosteronesynthaseinhibitorbaxdrostatsignificantlylowersbloodpressureinpatientswithresistanthypertension AT varzidehfahimeh theselectivealdosteronesynthaseinhibitorbaxdrostatsignificantlylowersbloodpressureinpatientswithresistanthypertension AT jankauskasstanislovass theselectivealdosteronesynthaseinhibitorbaxdrostatsignificantlylowersbloodpressureinpatientswithresistanthypertension AT kansakarurna theselectivealdosteronesynthaseinhibitorbaxdrostatsignificantlylowersbloodpressureinpatientswithresistanthypertension AT delucaantonio theselectivealdosteronesynthaseinhibitorbaxdrostatsignificantlylowersbloodpressureinpatientswithresistanthypertension AT santulligaetano theselectivealdosteronesynthaseinhibitorbaxdrostatsignificantlylowersbloodpressureinpatientswithresistanthypertension AT forzanoimma selectivealdosteronesynthaseinhibitorbaxdrostatsignificantlylowersbloodpressureinpatientswithresistanthypertension AT monepasquale selectivealdosteronesynthaseinhibitorbaxdrostatsignificantlylowersbloodpressureinpatientswithresistanthypertension AT varzidehfahimeh selectivealdosteronesynthaseinhibitorbaxdrostatsignificantlylowersbloodpressureinpatientswithresistanthypertension AT jankauskasstanislovass selectivealdosteronesynthaseinhibitorbaxdrostatsignificantlylowersbloodpressureinpatientswithresistanthypertension AT kansakarurna selectivealdosteronesynthaseinhibitorbaxdrostatsignificantlylowersbloodpressureinpatientswithresistanthypertension AT delucaantonio selectivealdosteronesynthaseinhibitorbaxdrostatsignificantlylowersbloodpressureinpatientswithresistanthypertension AT santulligaetano selectivealdosteronesynthaseinhibitorbaxdrostatsignificantlylowersbloodpressureinpatientswithresistanthypertension |